TGF-β is an anti-inflammatory cytokine whose signaling is negatively controlled by Smad7. Previously, we established a role for Smad7 in the generation of autoreactive T cells; however, the function of Smad7 in dendritic cells (DCs) remains elusive. Here, we demonstrate that DC-specific Smad7 deficiency resulted in elevated expression of the transcription factors Batf3 and IRF8, leading to increased frequencies of CD8 +
CD103
+ DCs in the spleen. Furthermore, Smad7-deficient DCs expressed higher levels of indoleamine 2,3-dioxygenase (IDO), an enzyme associated with tolerance induction. Mice devoid of Smad7 specifically in DCs are resistant to the development of experimental autoimmune encephalomyelitis (EAE) as a result of an increase of protective regulatory T cells (Tregs) and reduction of encephalitogenic effector T cells in the central nervous system. In agreement, inhibition of IDO activity or depletion of Tregs restored disease susceptibility. Intriguingly, when Smad7-deficient DCs also lacked the IFN-γ receptor, the mice regained susceptibility to EAE, demonstrating that IFN-γ signaling in DCs mediates their tolerogenic function. Our data indicate that Smad7 expression governs splenic DC subset differentiation and is critical for the promotion of their efficient function in immunity.
conditional gene targeting | dendritic cells | EAE | Smad7 | tolerance induction T ransforming growth factor (TGF)-β is a pleiotropic cytokine essential for immune homeostasis and tolerance. Systemic loss of TGF-β results in lethal multiorgan autoimmunity as a result of destructive autoreactive leukocyte infiltration into various organs (1) (2) (3) (4) (5) . TGF-β signaling is tightly regulated to ensure equilibrium of the immune system. Smad7 is a potent negative regulator of TGF-β signaling and prevents the binding of Smad2 and Smad3 to the TGF-β receptor II, which is required for TGF-β signal transduction. In addition, together with Smurf, Smad7 targets the TGF-β receptor for proteasomal degradation, which results in the termination of TGF-β signaling (6) . Although Smad7 is expressed upon TGF-β signaling, other stimuli such as interferon (IFN)-γ can induce Smad7 expression (7) .
Dendritic cells (DCs) are professional antigen-presenting cells that constantly sample their environment for foreign and selfantigens and thus play a prominent role in balancing immunity vs. tolerance (8, 9) . DCs constitute a heterogeneous family of cells consisting of two main populations, namely conventional DCs and plasmacytoid DCs (pDCs). Conventional DCs are mainly composed of CD11b + , CD8 + , and CD103 + subsets. DC development and subset differentiation are governed by the orchestrated expression of specific transcription and growth factors (10, 11) . Development of CD8 + and CD103 + DCs is dependent on expression of the transcription factors Batf3 (basic leucine zipper transcriptional factor ATF-like 3) and IRF8 (interferon regulatory factor 8), yet stimuli that induce or repress their expression in vivo remain poorly defined (12, 13) . CD8
+ and CD103 + DCs contribute to central (14) , as well as peripheral tolerance induction in part because of their ability to produce high amounts of TGF-β (11, 15, 16) . In general, DCs can secrete and respond to TGF-β and stimulation with TGF-β in vitro retained DCs in an immature state (17) . In contrast, conditional deletion of the TGF-β receptor II in DCs did not alter DCs maturation in vivo but resulted in the spontaneous development of autoimmunity (18) , highlighting the importance for TGF-β signaling specifically in DCs for the maintenance of tolerance. TGF-β can induce indoleamine 2,3-dioxygenase (IDO) expression in DCs (19) ; IDO is an enzyme involved in tryptophan catabolism with immunosuppressive functions (20) . During inflammation, IDO expression can also be induced by IFN-γ (19), thereby limiting excessive immune reactions. To date, it has not been addressed to our knowledge whether Smad7 signaling in DCs is involved in the regulation of IDO expression. Experimental autoimmune encephalomyelitis (EAE) represents a murine model for multiple sclerosis (MS) in which CNS-autoreactive T cells induce a demyelinating disease. Although DCs play an important role in inducing CNS-autoreactive T cells (21) , ablation or absence of CD11c-positive DCs results in exacerbated disease progression, suggesting an additional Significance Smad7 is a negative regulator of TGF-β signaling, a cytokine with anti-inflammatory properties. Although TGF-β was implicated in the development and function of dendritic cells (DCs), the in vivo role of Smad7 in DCs remains elusive. Here, we demonstrate that DC-specific Smad7 deletion affects the development of splenic CD8 +
+ DCs by regulating expression of the transcription factors Batf3 and IRF8. In addition, Smad7 directs DC function by regulating the expression of indoleamine 2,3-dioxygenase in response to IFN-γ signaling. Hence, absent Smad7 in DCs mediates resistance of mice to the development of autoimmunity via protective regulatory T-cell induction. These findings demonstrate that Smad7 expression governs splenic DC subset differentiation and affects tolerogenic DC function in vivo.
regulatory function of DCs during EAE (22) . Mice harboring DCs with impaired TGF-β receptor II signaling exhibit increased susceptibility to EAE and develop a more severe course of disease (23) . Moreover, elevated Smad7 levels were detected in T cells from patients with MS at the stage of active disease, as well as in mice subjected to EAE (24) . Thus far, the role of Smad7 in DCs during steady state and EAE remains elusive.
By using DC-specific Smad7-KO mice, we reveal a function of Smad7 as regulator of Batf3-and IRF8-mediated development of CD8
+

CD103
+ splenic DCs. Moreover, we demonstrate a critical role of Smad7 in inhibition of IDO-driven Treg induction able to HPRT of purified splenic CD11c + DCs isolated from S7 ΔDC (n = 4) or control animals (n = 4). One representative of five independent experiments is depicted.
(B) FACS plots and total cell counts of inguinal LN (Upper) and splenic DCs (Lower) derived from S7 ΔDC (n = 7) or controls (n = 6). Cells were gated on CD90. 
+ cells of S7 ΔDC (n = 7) or control mice (n = 6) is depicted. One representative of three independent experiments is depicted. Bar graphs depict mean value ± SEM. Statistical significance was assessed by using Student's t test (*P ≤ 0.05, **P ≤ 0.005, and ***P ≤ 0.0005).
attenuate disease outcome of EAE, and we show that IFN-γ signaling in DCs is necessary for tolerance induction by Smad7-deficient DCs. (Fig. 1B) . When we further analyzed splenic DC subsets in more detail, we detected a significant increase in the proportion of CD8 + DCs and, in particular, the CD8 +
Results
Smad7 Deficiency Enhances the Development of CD8
CD103
+ DC subset involved in tolerance induction (11, (14) (15) (16) (Fig. 1C, Lower) . In contrast, we did not notice any changes in the composition of DC subsets in the LN (Fig. S1A) . Moreover, frequencies and total cell counts of pDCs in LN and spleen of naïve mutant mice were indistinguishable from those in WT controls (Fig. S1B) 
+ DC development (12, 13) . Previously, it was demonstrated that TGF-β induces IRF8 expression in DCs, which is inhibited by Smad7 overexpression (29) . Similarly, IFN-γ stimulation induces IRF8 expression during inflammation (30, 31) . However, it is not yet clear which stimuli control expression of Batf3. Therefore, we isolated splenic DCs from S7 ΔDC mice and treated them for 24 h with TGF-β or IFN-γ. Quantitative RT-PCR analysis revealed significantly increased expression of Irf8 in splenic S7
ΔDC DCs under both stimulation conditions compared with control cells (Fig. 2 A and C) , indicating that Smad7 affects transcriptional factors controlling DC lineage commitment in the spleen. As depicted in Fig. 2 B and D, TGF-β and IFN-γ induced expression of Batf3 in splenic DCs, which was elevated in cells lacking Smad7. Taken together, these data indicate that Smad7 is a negative regulator of Batf3 and Irf8 expression, and its absence promotes the development of Batf3-and IRF8-dependent splenic CD8 +
+ DCs in S7 ΔDC mice.
Lack of Smad7 in DCs Does Not Affect T-Cell Homeostasis in the Steady
State. Next, we tested whether loss of Smad7 in DCs affected T-cell development, subset differentiation, or activation during the steady state. Deletion of Smad7 in DCs had no impact on T-cell development in the thymus (Fig. S2A, Upper) . Likewise, the splenic B/T-cell ratio was comparable between S7 ΔDC and control animals ( Fig. S2A , Middle). In accordance with the unaltered expression of MHC-II and costimulatory molecules by Smad7-deficient DCs, no difference in the activation status of CD4 + T cells could be detected. The total number of naïve, effector, and memory CD4 +
T cells was unaltered in S7
ΔDC mice compared with controls ( Fig. S2A, Lower) . Notably, despite the increased frequency of CD8 +
CD103
+ splenic DCs, cells that were previously implicated in tolerance induction (11, (14) (15) (16) , the numbers of Tregs in LN and spleens of S7 ΔDC mice remained similar to controls (Fig. S2B ). In conclusion, loss of Smad7 specifically in DCs does not affect T-cell homeostasis during the steady state.
DCs Devoid of Smad7 Mediate Resistance to EAE. As S7 ΔDC mice exhibited increased levels of CD8 +
+ splenic DCs previously associated with tolerance induction, we asked whether the lack of Smad7 in DCs could influence autoimmunity. We therefore induced active EAE in these mice by using myelin oligodendrocyte glycoprotein (MOG) peptide. Intriguingly, S7
ΔDC mice were resistant to EAE compared with control animals (Fig. 3A) . When we analyzed the CNS of these mice at the peak of disease, we detected a significant decrease in CNS-infiltrating CD90.2 + T cells ( Fig. 3B ) and, among them, a significant reduction in CD4
+ T cells compared with control mice (Fig. 3C , Upper). To determine the level of MOG -specific effector CD4
+ T cells infiltrating the CNS of S7 ΔDC mice, we restimulated CNS-infiltrating cells with MOG peptide and measured the expression of CD40 ligand (CD40L), which is transiently expressed upon T-cell activation (32) . We found that the lower number of T cells in the CNS of the S7 ΔDC mice was the result of a reduction in antigen-specific CD4 + T cells (Fig. 3C , Middle). Although there was no difference in the ratios of antigen-specific Th1 and Th17 cells or IL-17A and IFN-γ double producers, total cell counts exhibited fewer CNSinfiltrating Th1 and Th17 cells and significantly fewer T cells producing IL-17A and IFN-γ in S7 ΔDC mice (Fig. 3C , Bottom). Together, these data indicate that deletion of Smad7 in DCs attenuates the differentiation and infiltration of pathogenic T-cell populations into the CNS. As we have previously shown, DCs directly affect the development of peripherally induced Tregs during EAE (22) . In agreement, we detected increased numbers of Tregs in S7 ΔDC mice in secondary lymphoid organs and significantly increased percentages of Tregs in the CNS (Fig. 3D ). In conclusion, loss of Smad7 in DCs reduces the susceptibility of mice to EAE, probably as a result of an enlarged Treg compartment.
T-Cell Priming During EAE Is Independent of Smad7 Expression in DCs.
Next we sought to assess whether disease resistance of S7 ΔDC mice might also result from impaired T-cell priming. As antigen uptake and presentation by DCs is a crucial step in eliciting an immune response, we addressed whether loss of Smad7 might affect the antigen presentation capacity of DCs. Therefore, we induced EAE in S7
ΔDC and control mice by s.c. immunization with MOG 35-55 / Complete Freund's Adjuvant (CFA) emulsion containing beads labeled with FITC, which enabled us to identify FITC + DCs after antigen uptake and follow their migration to the draining LN (dLN). Analysis of these mice 1, 2, and 3 d after immunization revealed a similar frequency of FITC-labeled CD11c
DCs in the dLN of S7
ΔDC and control mice ( Fig. S3A ), indicating that DC antigen uptake and migration was not affected by the deletion of Smad7. Further in vitro analysis revealed unaltered secretion of TGF-β by Smad7-deficient DCs upon stimulation with LPS and CD40L (Fig. S3B) . Next, we investigated whether DC maturation might be altered in the absence of Smad7. Mice were immunized with the MOG peptide, and the activation status of CD11c
high migratory DCs present in the dLN was monitored on a daily basis. We did not detect any difference in CD80 or CD86 expression between Smad7-deficient and control DCs, as indicated by their similar mean fluorescence intensity 
Foxp3
+ Tregs of S7 ΔDC (n = 8) and control mice (n = 7) at the peak of disease (day 15; Middle and Lower, respectively). One representative of four independent experiments is depicted. Bar graphs depict mean value ± SEM. Statistical significance was assessed by using (A) EAE AUC followed by Student's t test and (B-D) Student's t test (*P ≤ 0.05, **P ≤ 0.005, and ***P ≤ 0.0005). Bar graphs represent mean value ± SEM. Statistical significance was assessed by Student's t test (A, B, and E), EAE AUC followed by two-way ANOVA and Bonferroni posttests (C), or two-way ANOVA and Bonferroni posttests (D) (*P ≤ 0.05, **P ≤ 0.005, and ***P ≤ 0.0005).
(MFI; Fig. S3C ). These findings were further confirmed by using GM-CSF-derived bone marrow DCs (BMDCs), left untreated or treated with LPS, in which MHC-II, CD80, CD86, and CD40 expression levels were comparable to those in controls (Fig. S3D) (Fig. S4A) . Hence, Smad7-deficient DCs displayed a comparable ability to induce MOG-specific T-cell proliferation as determined by in vitro coculture of carboxyfluorescein succinimidyl ester (CFSE)-labeled 2D2 T cells with splenic DCs (Fig. S4B) or GM-CSFderived BMDCs (Fig. S4C ) from S7 ΔDC mice or controls. Similarly, Smad7-deficient DCs polarized naïve T cells toward Th1 and Th17 cells to the same extent as control DCs when using MOG 35-55 -pulsed splenic DCs or BMDCs and naïve 2D2 T-cell cocultures (Fig. S5) . Taken (Fig. 4A) 
CD103
+ DC subsets compared with controls (Fig. 4B) . To investigate whether IDO production by Smad7-deficient DCs was responsible for disease protection, we inhibited IDO activity by treatment with 1-methyl-D-tryptophan (1-MT). As depicted in Fig. 4C, 1 -MT treatment as of the day of immunization restored disease susceptibility of S7 ΔDC mice to comparable levels as seen in 1-MT-treated controls (see also Fig. S6) . Analysis of the CNS infiltrates in vehicle and 1-MT-treated mice confirmed that IDO inhibition also largely restored the numbers of encephalitogenic Th1, Th17, and IL-17A + IFN-γ + double-producing MOGspecific effector CD4 + T cells in the CNS of S7 ΔDC mice (Fig. 4D) . In addition, when we analyzed inguinal LNs of S7 ΔDC mice 10 d after EAE immunization, a time point at which Treg cells in response to MOG /CFA are augmented, we noted that 1-MT treatment quenched the elevated number of Tregs detected in S7 ΔDC mice to comparable amounts as in 1-MT-treated controls (Fig. 4E) . Taken together, these results strongly suggest that augmented IDO expression by Smad7-deficient DCs contributes to the higher Treg numbers and hence plays a prominent role in the reduced susceptibility to EAE observed in S7 ΔDC mice. Increased levels of IDO might not only affect Treg cell generation but, at the same time, also suppress effector T-cell differentiation.
To discriminate the relative contribution of Tregs to disease outcome, S7 ΔDC mice were treated with an anti-CD25 depleting antibody (PC61) or with an isotype control antibody before disease induction (Fig. 5A) . As expected, control antibody treatment did not change the course of disease in WT, and S7 ΔDC mice retain their resistance (Fig. 5A, Left) . In contrast, when injected with PC61, WT mice developed exacerbated disease, with approximately two times higher mean clinical scores compared with control antibody-treated mice (Fig. 5A , Left and Right). Furthermore, PC61-treated WT mice failed to resolve EAE, unlike WT controls. Intriguingly, Treg depletion rendered S7 ΔDC mice susceptible to severe EAE. Disease progression of PC61-treated S7 ΔDC and WT mice was characterized by comparable mean clinical scores and similar lack of EAE remission (Fig. 5A, Right) DC-specific absence of Smad7 resulted in reduced EAE susceptibility, which was mediated by increased IDO levels driving the induction of more protective Tregs. As IDO expression in DCs is triggered upon IFN-γ signaling, we analyzed whether signaling to this cytokine might be responsible for the elevated IDO levels and the resistance of S7 ΔDC mice to EAE. Therefore, S7 ΔDC mice were crossed to animals that allow the conditional deletion of the IFN-γ receptor 2 (IFN-γR2), resulting in mice that lack Smad7 and IFN-γ signaling specifically in DCs (IFN-γR2 ΔDC S7 ΔDC mice). As depicted in Fig. 6 , simultaneous deletion of IFN-γ signaling and Smad7 in DCs restored EAE susceptibility of S7 ΔDC mice, whereas IFN-γR2 ΔDC S7 +/−ΔDC mice developed disease similar to WT controls. These data suggest that Smad7 regulates IDO expression in DCs when exposed to IFN-γ in vivo and that resistance of S7 ΔDC mice to EAE is mainly driven by uncontrolled IFN-γ-mediated IDO expression in DCs.
In conclusion, our data establish a critical role for Smad7 during the differentiation of IDO + tolerogenic DCs during inflammation and its physiological relevance in Treg-mediated tolerance of autoimmune inflammation.
Discussion
Studies using genetically modified mice established a prominent role for TGF-β in anti-inflammatory responses important for the maintenance of immune homeostasis and the establishment of tolerance (1-5), including the observation that TGF-β signaling in DCs is a prerequisite for the control of EAE (23) . On the contrary, little is known about the function of the TGF-β-negative regulator Smad7 in DCs. By using mice with a DC-specific deletion of Smad7 (S7 ΔDC ), we characterized the role of Smad7 during DC homeostasis and function, particularly its impact on the outcome of CNS autoimmunity. Except for an increase in CD8 +
CD103
+ DCs in the spleen, we did not observe any other obvious differences between S7
ΔDC and control animals under steady-state conditions. When stimulated with IFN-γ or TGF-β, Smad7-deficient DCs expressed elevated levels of the transcription factors IRF8 and Batf3. Following IFN-γ stimulation, loss of Smad7 led to higher IDO production by DCs and, consequently (19) , an increased percentage and absolute number of Tregs in vivo. In line, S7 ΔDC mice were resistant to the induction of EAE by MOG immunization and did display only minor signs of CNS demyelination compared with control animals.
In the steady state, DC-specific Smad7 deletion resulted in a shift in splenic DC populations toward the differentiation of CD8 +
+ DCs. This bias was mediated by increased expression of the corresponding lineage-defining transcription factors Batf3 and IRF8. Previously, it was shown that the stimulation of murine DC progenitor cells with TGF-β led to increased development of conventional DCs at the expense of pDCs (33) . However, the resulting conventional DC subsets and their function were not further analyzed in this study. Development of CD8 + and CD103 + DCs is dependent on the transcription factors IRF8 and Batf3 (12, 13) . To date, the mediators that induce these transcription factors during DC differentiation remain poorly defined. As S7 ΔDC mice displayed increased frequencies of splenic CD8 + CD103 + DCs associated with elevated expression of IRF8 and Batf3, our data suggest that Smad7 negatively influences expression of CD8 +
+ lineage-defining transcription factors in response to TGF-β. This conclusion is supported by a previous publication in which blockade of the TGF-β pathway by ectopic expression of Smad7 abolished the up-regulation of IRF8, which indicates a direct role for Smad7 in IRF8 repression (29) . Smad7 is able to bind DNA through its MH2 domain (34, 35) and to associate with the histone deacetylases HDAC1 and SIRT1, thus regulating transcription by repressing promoter activity (36) (37) (38) . However, whether Smad7 affects CD8 +
+ DC differentiation by direct repression of IRF8 and Batf3 promoter activity or regulates another unknown factor(s) controlling Batf3 and IRF8 expression remains elusive. Although pDC development is likewise dependent on IRF8, the percentages and absolute numbers of pDCs in S7
ΔDC mice remained unchanged. Although CD11c-Cre mice can effectively target all DC subsets, including pDCs (25) , the efficiency of Cre-mediated recombination also depends on the accessibility of the target gene, as we have recently revealed that pDCs were not depleted by using the inducible diphtheria toxin receptor (iDTR) system when targeted by the same CD11c-Cre (22) . Alternatively, it is conceivable that other molecules besides Smad7 control IRF8 expression in pDCs. Steady-state expression of MHC-II and costimulatory molecules was not affected by deletion of Smad7. Hence, T-cell homeostasis and activation were unchanged in S7 ΔDC mice, including similar numbers of Tregs despite the increased frequency of splenic CD8 +
+ DCs. In contrast, when subjected to EAE, S7 ΔDC mice displayed significantly milder disease progression accompanied by elevated numbers of CNS-infiltrating Tregs and reduced numbers of MOG-reactive effector T cells based on CD40L expression upon MOG restimulation of CNS-infiltrating lymphocytes (22, 32) . Because lack of Smad7 also did not affect DC maturation, i.e., antigen presentation or costimulation, these data strongly suggest that, upon EAE induction, absence of Smad7 in DCs led to augmented numbers of Tregs, which in turn suppressed differentiation of encephalitogenic effector T cells. In line with this, abrogated TGF-β receptor signaling in DCs resulted in severe EAE (23) and spontaneous multiorgan autoimmune disease with increasing age (18) , indicating that TGF-β signaling is critical for the suppressive function of the DC. However, these studies did not detect differences in the development of DC subpopulations or in IDO expression. It was recently demonstrated that absent TGF-β signaling in mature CD4 + T cells does not lead to breakdown of peripheral tolerance (39) , thus suggesting that TGF-β signaling in DCs and not in T cells is mandatory for peripheral tolerance. On the contrary, mice with a T-cell-specific deletion of Smad7 are resistant to the induction of EAE (24) . Our new findings support a critical role of Smad7 as an inhibitor of a tolerogenic DC phenotype. In particular, CD8 +
+ DCs have been previously linked to tolerance induction in part as a result of increased IDO expression, which mediates enhanced Treg differentiation upon challenge (16, 19, (40) (41) (42) . In agreement with the requirement of a proinflammatory stimulus, in our study, all conventional DC subsets devoid of Smad7 exhibited elevated IDO expression following IFN-γ stimulation in vitro and during EAE. Indeed, IDO plays a prominent role in MS and during EAE, as increased IDO protein levels are detected in the CNS and peripheral organs during these diseases (43) (44) (45) (46) . By using IDO −/− mice, it was shown that IDO augments Tregs via tryptophan metabolites and suppresses encephalitogenic T-cell responses in EAE (20) . IDO expression is induced upon TGF-β as well as IFN-γ signaling (19, 40) , and likewise IFNγR −/− mice lack IDO activity (47) . Hence, during EAE, IDO might be produced in response to IFN-γ and contributes to terminate inflammation in a negative feedback loop (43) (44) (45) (46) . However, most studies addressing the tolerogenic function of IDO used models of global overexpression or inhibition of IDO. Here, we provide evidence that, upon inflammation, DC-specific IDO expression supports Tregmediated tolerance and that Smad7 controls this tolerogenic DC phenotype. Moreover, our data suggest that this IDO-mediated resistance to EAE, observed in S7 ΔDC mice, is dependent on IFN-γ signaling as DC-specific ablation of IFN-γR2 and Smad7 resulted in normal disease development.
Although IFN-γ was originally described as a proinflammatory cytokine, as its expression was associated with pathogenic Th1 cells, more recently it became evident that IFN-γ actually ameliorates EAE disease progression (42, (48) (49) (50) (51) . Moreover, the tolerogenic function of IFN-γ is not limited to EAE but similarly applies to other autoimmune diseases such as autoimmune myocarditis (52) and collagen-induced arthritis (53, 54) . Our data indicate that Smad7 expression in DCs in response to IFN-γ during inflammation would not only inhibit TGF-β signaling but, at the same time, suppress expression of the transcription factor IRF8 that is important for IDO induction. Abrogated IDO expression in mice with DCs lacking the IFN-γR2 and Smad7 in turn results in reduced Treg differentiation and consequently susceptibility to EAE. In the time course analyzed here, we did not observe a difference in EAE between controls and mice with DC-specific IFN-γR2 deficiency alone. This may indicate that, under strong inflammatory conditions in acute EAE, the effect of IFN-γ-mediated IDO expression and Treg induction may be well counterbalanced by Smad7 and inflammatory cytokines such as IL-6 and IL-1β.
Given that Smad7 in DCs represents a key molecular switch that regulates IDO expression during ongoing inflammation, Smad7 inhibition may provide a promising therapeutic approach for the treatment of chronic inflammatory diseases. Indeed, Smad7 antisense oligonucleotide therapy suppressed EAE (55) and experimental colitis in mice (56) and is currently being tested in a phase III clinical trial with promising prospects in patients with Crohn's disease (ref. 57; www.clinicaltrials.gov: NCT02596893). In addition, simvastatin efficiently abrogates Smad7, resulting in a higher frequency of FoxP3 + Tregs in mice (58) . Notably, none of these drugs were cell type-specific. Based on our findings, a Smad7 inhibitor should offer an attractive approach to treat autoimmune patients while minimizing potential adverse side effects.
In conclusion, in this study, we have identified a crucial role for Smad7 in DC differentiation and function. In the steady state, Smad7 regulates the expression of the transcription factors Batf3 and IRF8 that promote the development of CD8 +
+ DCs in the spleen. During inflammation, Smad7 governs the tolerogenic function of conventional DCs by regulating IDO-mediated Treg induction. Hence, DC-specific Smad7 deletion alleviates EAE, which may be exploited for therapy of autoimmune diseases.
Materials and Methods
Mice. CD11c-Cre +/− mice (25) were bred to Smad7 fl/fl mice (24) ). All animals were on a C57BL/6 background and kept under specific pathogen-free conditions at the central animal facility in Mainz. Experiments were performed in accordance with guidelines of the institutional animal care and use committee of the University of Mainz.
Induction and Clinical Evaluation of EAE. Eight-to 10-wk-old mice were injected with 50 μg MOG in CFA containing 8 mg/mL concentration of heat-inactivated Mycobacterium tuberculosis H37RA (Difco Laboratories) into the tail base. On days 0 and 2, mice were injected intraperitoneally with 200 ng pertussis toxin (Sigma-Aldrich). Daily scoring was performed using the following criteria: 0, healthy; 1, limp tail; 2, partial hindlimb weakness/ ataxia; 3, paralysis of at least one hindlimb; 4, complete hindlimb paralysis; 5, partial forelimb paralysis; and 6, moribund/dead. In Vitro DC-Mediated Th1 and Th17 Cell Differentiation. A total of 40,000 DCs derived from spleen and LN, enriched by using Dynabeads Mouse DC enrichment kit (Invitrogen), were cocultured with 400,000 CD4 + CD62L + MACSpurified naïve 2D2 T cells for 6 d in RPMI media (supplemented with 10% (vol/vol) FCS, 2 mM glutamine, 100 units/mL penicillin, 100 mg/mL streptomycin, represents mean value ± SEM. One representative of two independent experiments is depicted. Statistical significance was assessed by using AUC followed by one-way ANOVA and Newman-Keuls multiple comparison test (*P ≤ 0.05, **P ≤ 0.005, and ***P ≤ 0.0005).
and 50 mM β-mercaptoethanol) containing medium alone or medium supplemented with 20 μg/mL MOG Intracellular staining for IL-17A, IFN-γ and IDO1 was performed after cell restimulation for 4 h with 50 ng/mL phorbol 12-myristate 13-acetate, 500 ng/mL ionomycin, and 5 mg/mL brefeldin A. For discrimination of MOG -specific effector T cells, cells were stimulated with 20 μg/mL MOG 35-55 for 3 h, and then 5 mg/mL brefeldin A was added, and cells were cultured for an additional 3 h. Antibodies specific for mouse IL-17A (clone TC11-18H10.1), IFN-γ (clone XMG1.2), Foxp3 (clone FJK-16s; eBioscience), and IDO1 (clone 2E2.6; Novus Biologicals) were used for intracellular cytokine staining. Intracellular stainings were performed according to the protocol of the BD Cytofix/Cytoperm kit (BD Biosciences) or Foxp3/Transcription Factor Staining Buffer set (eBiosciences). Cells were analyzed by using a FACSCanto device (BD Biosciences) with FACSDiva software (BD Biosciences) or FACScan (BD Biosciences) with CellQuest (BD Biosciences) software. Postacquisition analysis was performed by using FlowJo or CellQuest software.
Immunohistochemistry. Histology was performed as described previously (61) . Mice were perfused during deep anesthesia with ice-cold saline solution. Spinal cords were removed and fixed in 4% (vol/vol) buffered formalin. Then, spinal cords were dissected and embedded in paraffin before staining with H&E, Luxol fast blue to assess the degree of demyelination, macrophage-3 antigen (clone M3/84, dilution 1:200; BD Pharmingen) for macrophages/ microglia, CD3 for T cells (clone CD3-12, dilution 1:100; Serotec), B220 for B cells (clone RA3-6B2, dilution 1:200; BD Pharmingen), and deposition of APP (clone 22C11, dilution 1:3,000; Millipore), which reflects axonal damage. Secondary antibodies were polyclonal rabbit anti-mouse biotinylated (E0464, lot 00073409; DAKO) and used in a dilution of 1:200, in combination with avidinperoxidase (A7419, 1:1,000; Sigma-Aldrich). Tissue sections were evaluated on an Olympus BX-61 microscope with the use of cell-P software (Olympus).
Quantitative Real-Time PCR. Total mRNA was isolated by using the RNEasy kit (Qiagen) from MACS-purified CD11c + cells or Dynabeads DC-enriched splenic cells. cDNA preparation was performed by using SuperScript reverse transcriptase (Invitrogen). Quantitative real-time PCR of mRNA coding for Smad7, IRF8, Batf3, IDO1, and IDO2 was performed by using primers from Qiagen and the QuantiTect SYBR Green RT-PCR kit. The relative mRNA amounts were determined by normalization to the housekeeping genes GAPDH or hypoxanthine guanine phosphoribosyl transferase (HPRT). The expression levels of mRNA were calculated by using the ΔC T method and normalized to the WT control.
TGF-β Cytokine Bead Array. For the measurement of TGF-β cytokine production, 0.5 × 10 6 DCs were stimulated with or without 1 μg/mL LPS (Escherichia coli 026.B6; Sigma-Aldrich) in RPMI [supplemented with 10% (vol/vol) FCS, 2 mM glutamine, 100 mg/mL streptomycin, 100 U/mL penicillin, and 5 mM β-mercaptoethanol] overnight. Supernatants were harvested, and cells were washed with PBS solution and stimulated with soluble CD40L (sCD40L; PeproTech) for an additional 24 h when supernatants were collected. The levels of TGF-β in supernatants of stimulated cells were determined by cytometric bead assay (Bender MedSystems) according to the manufacturer's instructions. Analysis was performed on a FACSCanto-II (BD Biosciences), and the concentration of measured cytokines was calculated by using FCAP Array software (BD Biosciences).
Statistical Analysis. Values are presented as mean ± SEM. Statistical significance between two groups was assessed by using two-tailed Student's t test. When comparing two groups with two additional treatments, two-way ANOVA and Bonferroni posttests were used. When comparing two EAE groups, statistical significance was determined by measurements of EAE area under the curve (AUC) followed by Student's t test. EAE significance of two groups with two different treatments was assessed by measurement of EAE AUC followed by two-way ANOVA and Bonferroni posttests. P > 0.05 was considered not significant.
